Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary

Andrew Krasner1, Jonathan L Halperin

  • 1The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA.

Insights

Patients with atrial fibrillation needing anticoagulation benefit from warfarin. Combining warfarin with dual antiplatelet therapy increases bleeding risk, prompting research into alternative strategies for stroke prevention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Atrial fibrillation patients with thromboembolism risk benefit from oral anticoagulation.
  • Dual antiplatelet therapy is crucial after drug-eluting stent placement.
  • Combining warfarin with dual antiplatelet therapy significantly elevates bleeding risk.

Purpose of the Study:

  • To review the challenges and evolving strategies in managing anticoagulation for patients with atrial fibrillation undergoing percutaneous coronary intervention.
  • To explore the implications of novel oral anticoagulants and P2Y12 inhibitors in this patient population.

Main Methods:

  • Review of recent clinical trials and pharmacological data.
  • Analysis of treatment regimens for patients with atrial fibrillation and coronary artery disease.

Main Results:

  • Omitting aspirin in dual therapy regimens has shown promising results in reducing bleeding.
  • Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) and potent antiplatelet agents (prasugrel, ticagrelor) add complexity to treatment decisions.

Conclusions:

  • Managing anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention is complex.
  • Future research is needed to identify safer and more effective antithrombotic strategies for this high-risk group.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...